Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

被引：262

作者：

Cardoso, F. ^{[1
,2
]}

Bartlett, J. M. S. ^{[3
,4
]}

Slaets, L. ^{[5
]}

van Deurzen, C. H. M. ^{[6
,7
]}

van Leeuwen-Stok, E. ^{[7
]}

Porter, P. ^{[8
,9
,10
]}

Linderholm, B. ^{[11
,12
]}

Hedenfalk, I. ^{[13
]}

Schroder, C. ^{[7
,14
]}

Martens, J. ^{[7
,15
]}

Bayani, J. ^{[16
]}

van Asperen, C. ^{[7
,17
]}

Murray, M. ^{[18
]}

Hudis, C. ^{[19
,20
]}

Middleton, L. ^{[21
]}

Vermeij, J. ^{[22
]}

Punie, K. ^{[23
]}

Fraser, J. ^{[24
]}

Nowaczyk, M. ^{[25
]}

Rubio, I. T. ^{[26
]}

Aebi, S. ^{[27
]}

Kelly, C. ^{[28
]}

Ruddy, K. J. ^{[29
]}

Winer, E. ^{[30
]}

Nilsson, C. ^{[12
,31
]}

Dal Lago, L. ^{[32
]}

Korde, L. ^{[33
]}

Benstead, K. ^{[34
]}

Bogler, O. ^{[35
]}

Goulioti, T. ^{[36
]}

Peric, A. ^{[5
]}

Litiere, S. ^{[5
]}

Aalders, K. C. ^{[5
]}

Poncet, C. ^{[5
]}

Tryfonidis, K. ^{[5
]}

Giordano, S. H. ^{[37
,38
]}

机构：

[1] Champalimaud Fdn, Breast Unit, Champalimaud Clin Ctr, Ave Brasilia S-N, P-1400038 Lisbon, Portugal

[2] European Org Res Treatment Canc, Breast Canc Grp, Toronto, ON, Canada

[3] Ontario Inst Canc Res, Transformat Pathol, Toronto, ON, Canada

[4] Univ Edinburgh, Edinburgh, Midlothian, Scotland

[5] European Org Res & Treatment Canc EORTC Headquart, Brussels, Belgium

[6] Erasmus MC, Dept Pathol, Rotterdam, Netherlands

[7] Dutch Breast Canc Res Grp BOOG, Amsterdam, Netherlands

[8] Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA

[9] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA

[10] Univ Washington, Dept Pathol, Seattle, WA 98195 USA

[11] Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden

[12] Swedish Assoc Breast Oncologists, Lund, Sweden

[13] Lund Univ, Dept Clin Sci, Div Oncol & Pathol, Lund, Sweden

[14] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands

[15] Erasmus MC, Breast Canc Genom & Prote Lab, Rotterdam, Netherlands

[16] Ontario Inst Canc Res, Transformat Pathol, Toronto, ON, Canada

[17] Leiden Univ, Med Ctr, Dept Clin Genet, Leiden, Netherlands

[18] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA

[19] Mem Sloan Kettering Canc Ctr, Breast Med Serv, 1275 York Ave, New York, NY 10021 USA

[20] Weill Cornell Med Coll, New York, NY USA

[21] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[22] Hosp Network Antwerp ZNA, Dept Med Oncol, Antwerp, Belgium

[23] UZ Leuven, Dept Gen Med Oncol, Leuven, Belgium

[24] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[25] Specialist Hosp, Gdansk, Poland

[26] Hosp Univ Vall dHebron, Breast Surg Unit, Barcelona, Spain

[27] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland

[28] All Ireland Cooperat Oncol Res Grp ICORG, Dublin, Ireland

[29] Mayo Clin, Dept Oncol, Rochester, MN USA

[30] Dana Farber Canc Inst, Boston, MA 02115 USA

[31] Vastmanlands Hosp, Dept Oncol, Vasteras, Sweden

[32] Jules Bordet Inst, Dept Med Oncol, Brussels, Belgium

[33] Univ Washington, Seattle, WA 98195 USA

[34] Cheltenham Gen Hosp, Dept Oncol, Cheltenham, Glos, England

[35] Univ Texas MD Anderson Canc Ctr, Global Acad Programs, Houston, TX 77030 USA

[36] Breast Int Grp, Brussels, Belgium

[37] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA

[38] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷 / 02期

关键词：

male breast cancer; retrospective analysis; consortium; clinical and biological characteristics; LOBULAR CARCINOMA; KLINEFELTERS-SYNDROME; CONSENSUS GUIDELINES; RECOMMENDATIONS; EXPRESSION; MUTATIONS; ESTROGEN; THERAPY; PATIENT; BRCA2;

D O I：

10.1093/annonc/mdx651

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part I, a retrospective joint analysis of cases diagnosed during a 20-year period. Methods: Patients with follow-up and tumor samples, treated between 1990 and 2010, in 93 centers/9 countries. Samples were centrally analyzed in three laboratories (the United Kingdom, the Netherlands and the United States). Results: Of 1822 patients enrolled, 1483 were analyzed; 63.5% were diagnosed between 2001 and 2010, 57 (5.1%) had metastatic disease (M1). Median age at diagnosis: 68.4 years. Of 1054 M0 cases, 56.2% were node-negative (N0) and 48.5% had T1 tumors; 4% had breast conserving surgery (BCS), 18% sentinel lymph-node biopsy; half received adjuvant radiotherapy; 29.8% (neo) adjuvant chemotherapy and 76.8% adjuvant endocrine therapy (ET), mostly tamoxifen (88.4%). Per central pathology, for M0 tumors: 84.8% ductal invasive carcinomas, 51.5% grade 2; 99.3% estrogen receptor (ER)-positive; 81.9% progesterone receptor (PR)-positive; 96.9% androgen receptor (AR)-positive [ER, PR or AR Allred score >= 3]; 61.1% Ki67 expression low (< 14% positive cells); using immunohistochemistry (IHC) surrogates, 41.9% were Luminal-A-like, 48.6% Luminal-B-like/HER-2-negative, 8.7% HER-2-positive, 0.3% triple negative. Median follow-up: 8.2 years (0.0-23.8) for all, 7.2 years (0.0-23.2), for M0, 2.6 years (0.012.7) for M1 patients. A significant improvement over time was observed in age-corrected BC mortality. BC-specific-mortality was higher for men younger than 50 years. Better overall (OS) and recurrence-free survival (RFS) were observed for highly ER+(P = 0.001), highly PR+(P = 0.002), highly AR+disease (P = 0.019). There was no association between OS/RFS and HER-2 status, Ki67, IHC subtypes nor grade. Conclusions: Male BC is usually ER, PR and AR-positive, Luminal B-like/HER2-negative. Of note, 56% patients had T1 tumors but only 4% had BCS. ER was highly positive in> 90% of cases but only 77% received adjuvant ET. ER, PR and AR were associated with OS and RFS, whereas grade, Ki67 and IHC surrogates were not. Significant improvement in survival over time was observed.

引用

页码：405 / 417

页数：13

共 40 条

[1] Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
Anderson, William F.
Jatoi, Ismail
Tse, Julia
Rosenberg, Philip S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) : 232 - 239
[2] Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
Bartlett, John M. S.
Bayani, Jane
Marshall, Andrea
Dunn, Janet A.
Campbell, Amy
Cunningham, Carrie
Sobol, Monika S.
Hall, Peter S.
Poole, Christopher J.
Cameron, David A.
Earl, Helena M.
Rea, Daniel W.
Macpherson, Iain R.
Canney, Peter
Francis, Adele
McCabe, Christopher
Pinder, Sarah E.
Hughes-Davies, Luke
Makris, Andreas
Stein, Robert C.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (09):
[3] 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F.
Costa, A.
Senkus, E.
Aapro, M.
Andre, F.
Barrios, C. H.
Bergh, J.
Bhattacharyya, G.
Biganzoli, L.
Cardoso, M. J.
Carey, L.
Corneliussen-James, D.
Curigliano, G.
Dieras, V.
El Saghir, N.
Eniu, A.
Fallowfield, L.
Fenech, D.
Francis, P.
Gelmon, K.
Gennari, A.
Harbeck, N.
Hudis, C.
Kaufman, B.
Krop, I.
Mayer, M.
Meijer, H.
Mertz, S.
Ohno, S.
Pagani, O.
Papadopoulos, E.
Peccatori, F.
Penault-Llorca, F.
Piccart, M. J.
Pierga, J. Y.
Rugo, H.
Shockney, L.
Sledge, G.
Swain, S.
Thomssen, C.
Tutt, A.
Vorobiof, D.
Xu, B.
Norton, L.
Winer, E.
[J]. ANNALS OF ONCOLOGY, 2017, 28 (01) : 16 - 33
[4] ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F.
Costa, A.
Norton, L.
Senkus, E.
Aapro, M.
Andre, F.
Barrios, C. H.
Bergh, J.
Biganzoli, L.
Blackwell, K. L.
Cardoso, M. J.
Cufer, T.
El Saghir, N.
Fallowfield, L.
Fenech, D.
Francis, P.
Gelmon, K.
Giordano, S. H.
Gligorov, J.
Goldhirsch, A.
Harbeck, N.
Houssami, N.
Hudis, C.
Kaufman, B.
Krop, I.
Kyriakides, S.
Lin, U. N.
Mayer, M.
Merjaver, S. D.
Nordstrom, E. B.
Pagani, O.
Partridge, A.
Penault-Llorca, F.
Piccart, M. J.
Rugo, H.
Sledge, G.
Thomssen, C.
van't Veer, L.
Vorobiof, D.
Vrieling, C.
West, N.
Xu, B.
Winer, E.
[J]. ANNALS OF ONCOLOGY, 2014, 25 (10) : 1871 - 1888
[5] Recognizing features that are dissimilar in male and female breast cancer:: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay
Curigliano, G
Colleoni, M
Renne, G
Mazzarol, G
Gennari, R
Peruzzotti, G
de Braud, F
Robertson, C
Maiorano, E
Veronesi, P
Nolè, F
Mandalà, M
Ferretti, G
Viale, G
Goldhirsch, A
[J]. ANNALS OF ONCOLOGY, 2002, 13 (06) : 895 - 902
[6] Strategies in treating male breast cancer
Cutuli, Bruno
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) : 193 - 202
[7] Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
Eggemann, Holm
Ignatov, Atanas
Smith, Bobbie J.
Altmann, Udo
von Minckwitz, Gunter
Roehl, Freidrich W.
Jahn, Mark
Costa, Serban-Dan
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 465 - 470
[8] CARCINOMA OF THE MALE BREAST AND KLINEFELTERS-SYNDROME - IS THERE AN ASSOCIATION
EVANS, DB
CRICHLOW, RW
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1987, 37 (04) : 246 - 251
[9] Risk factors for male breast cancer - A case-control study from Scandinavia
Ewertz, M
Holmberg, L
Tretli, S
Pedersen, BV
Kristensen, A
[J]. ACTA ONCOLOGICA, 2001, 40 (04) : 467 - 471
[10] Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma
Faratian, Dana
Munro, Alison
Twelves, Christopher
Bartlett, John M. S.
[J]. HISTOPATHOLOGY, 2009, 54 (02) : 254 - 257

← 1 2 3 4 →